About this trial
Child-parent screening for familial hypercholesterolemia has been proposed to identify children and their parent who are carrier of mutations and with high risk for inherited premature coronary artery disease. The investigators assessed the efficacy and feasibility of such screening in primary care practice.
key scientific questions:
1. The 95th and 99th percentile of finger blood TC in children of 2 years old. 2. Mutations that contribute to high TC status ( serum TC \>99th percentiles) compared with international FH48 panel for FH genetic screening.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Receive routine child care
aged 1 - 3 years old ( date of investigate minus date of birth)
Disqualifiers
It is up to the researcher to decide whether it is suitable to participate in this research
Trial population
All community-children from slelected communities aged 1 to 3 who receive regular child care (programmed immunization vaccination clinic) within a prespecified study period
Trial design
Family-based
Cross-sectional
Treatments tested in this trial
no interventions
Other interventionit is a observational study, do not have interventions.
Treatment groups
Trial outcomes
Primary outcomes
The affected status of Familial Hypercholesterolemia
heterozygote or homozygote carriers of established FH mutations in LDLR, PSCK9 and APOB gene, including mutations included in the FH48 and new ones identified in Chinese children
Secondary outcomes
fasting total cholesterol level by Fingertip capillary blood test in children around 2 years old
affected status of known FH mutation
according to FH48
fasting serum LDL-c levels of children with finger TC over P95
Sponsors and contacts
Click on the lead sponsor to view all of their trials.